TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04987450
Drug: Methylprednisolone, prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
Study: NCT02410200
Drug: dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00534586
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCI 0.5 mcg/ml 1.0 mcg/ml
Study: NCT00534586
Drug: S-Ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
Study: NCT00534586
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: via face mask 0.40 Vol% 0.80 Vol%
Study: NCT01897896
Drug: SD-809
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
Study: NCT00235625
Drug: Curcuminoids C3 Complex®
DrugBank: Cumin (DB10864)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00707369
Drug: Amoxicillin and Metronidazole
Normalized name: omeprazole, amoxicillin and metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
Study: NCT02653560
Drug: Potassium chloride powder
Normalized name: potassium chloride Powder for Oral Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02653560
Drug: Potassium magnesium Citrate (KMgCit)
Normalized name: Potassium
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02653560
Drug: Potassium citrate powder
Normalized name: citric acid / potassium citrate Powder for Oral Solution
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01257893
Drug: Aspirin (acetylsalicylic acid)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin one 81 mg capsule per day for 10-14 consecutive days
Study: NCT04187690
Drug: Jin-shui Huan-xian granule
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin-shui Huan-xian granule will be administered 5days on and 2 days off for 52 weeks.
Study: NCT02451007
Drug: lurbinectedin (PM01183)
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02363127
Drug: subcutaneous progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous progesterone 25 mg/day
Study: NCT02363127
Drug: vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: vaginal progesterone in capsules 200 mg/3 times a day
Study: NCT02241031
Drug: thrombopoietin (TPO) and interleukin-11
Normalized name: Interleukin 11
DrugBank: Thrombopoietin (DB06534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
Study: NCT01832298
Drug: Simmitecan Hydrochloride for Injection
Normalized name: colestipol hydrochloride Granules for Oral Suspension
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
Study: NCT02399566
Drug: Erlotinib, Pemetrexed
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
Study: NCT02172261
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02172261
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00310843
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with HIV-1 infection who have taken or are currently taking nevirapine
Study: NCT00693199
Drug: amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5mg once daily for 28 days
Study: NCT00693199
Drug: terazosin
Normalized name: Terazosin
DrugBank: Terazosin (DB01162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: terazosin 2 mg once daily for 28 days
Study: NCT00693199
Drug: amlodipine plus terazosin
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5 mg plus terazosin 2 mg once daily for 28days
Study: NCT01177306
Drug: extended release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
Study: NCT00055887
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00055887
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00055887
Drug: efaproxiral
Normalized name: EFAPROXIRAL
DrugBank: Efaproxiral (DB08486)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00055887
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00055887
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00055887
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00397046
Drug: neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HKI-272
Study: NCT02607163
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
Study: NCT02607163
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
Study: NCT00383032
Drug: mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00057798
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00057798
Drug: vinorelbine ditartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01582555
Drug: dissolved N-Acetylcystine
DrugBank: Cystine (DB00138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
Study: NCT04155632
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
Study: NCT01160718
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
Study: NCT01160718
Drug: selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZD6244 75 mg p.o. bid
Study: NCT03001739
Drug: Urapidil Hydrochloride Injection
DrugBank: Urapidil (DB12661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
Study: NCT00124358
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02605967
Drug: Spartalizumab
Normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spartalizumab was administered via intravenous infusion at a dose of 400 mg every 4 weeks (Q4W). Spartalizumab is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
Study: NCT01482403
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: total daily dose of 1000 mg or 1200 mg for 24 weeks
Study: NCT01482403
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: total daily dose of 1000 mg or 1200 mg for 48 weeks
Study: NCT01482403
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 microgram subcutaneous once a week for 24 weeks
Study: NCT01482403
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 microgram subcutaneous once a week for 48 weeks
Study: NCT01482403
Drug: boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg three times a day for 24 weeks
Study: NCT01482403
Drug: boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg three times a day for 48 weeks
Study: NCT01482403
Drug: mericitabine
Normalized name: Mericitabine
DrugBank: Mericitabine (DB12045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg twice daily for 24 weeks
Study: NCT01482403
Drug: mericitabine placebo
DrugBank: Mericitabine (DB12045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mericitabine placebo
Study: NCT01482403
Drug: boceprevir placebo
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: boceprevir placebo
Study: NCT01482403
Drug: boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg three times a day for 44 weeks
Study: NCT04022213
Drug: 131 I-omburtamab
Normalized name: Omburtamab I-131
DrugBank: Omburtamab I-131 (DB17124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
Study: NCT01628770
Drug: Iron isomaltoside 1000
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
Study: NCT01628770
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg twice daily
Study: NCT04573478
Drug: Atrasentan
Normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT03942653
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin Acetate, SQ, Q4W
Study: NCT03942653
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab, IV, Q3W
Study: NCT04308590
Drug: relacorilant
Normalized name: Relacorilant
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relacorilant is supplied as 100 mg capsules for oral dosing.
Study: NCT01122368
Drug: micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV
Study: NCT02891954
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
Study: NCT02662582
Drug: Reldesemtiv
Normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT04624204
Drug: Pembrolizumab placebo (saline)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab placebo (saline) Q3W
Study: NCT04624204
Drug: Pembrolizumab placebo (saline)
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab placebo (saline) Q6W
Study: NCT04624204
Drug: Olaparib 300 mg BID
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg twice daily (BID)
Study: NCT04624204
Drug: Olaparib matching placebo
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib matching placebo BID
Study: NCT04624204
Drug: Etoposide 100 mg/m^2
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 100 mg/m\^2 intravenous (IV) Q3W, Day 1-3
Study: NCT04624204
Drug: Platinum, investigator's choice
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin titrated to an area under the plasma drug concentration time curve (AUC) of 5 mg/mL/min IV Q3W OR Cisplatin 75 mg/m\^2 IV Q3W on Day 1 of each cycle
Study: NCT03258593
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
Study: NCT03258593
Drug: Antihistamine
Normalized name: Antihistamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
Study: NCT00940121
Drug: mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT00940121
Drug: mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV solution
Study: NCT02550028
Drug: Oral levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
Study: NCT02550028
Drug: Intravenous phenobarbital
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
Study: NCT01126255
Drug: Clobetasol propionate 0.05%
Normalized name: CLOBETASOL PROPIONATE 0.05% OINT
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical application, once daily about 2 g, during 12 weeks
Study: NCT01126255
Drug: Progesterone 8%
Normalized name: progesterone 8% vaginal gel
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical application, once daily about 2 g, during 12 weeks
Study: NCT04477837
Drug: Apixaban 5 MG
Normalized name: apixaban 5 MG
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: frequency of heavy menstrual bleeding
Study: NCT04477837
Drug: Rivaroxaban 20 MG
Normalized name: rivaroxaban 20 MG
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: frequency of heavy menstrual bleeding
Study: NCT04477837
Drug: Edoxaban 60 MG
Normalized name: edoxaban 60 MG
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: frequency of heavy menstrual bleeding
Study: NCT04477837
Drug: Dabigatran 150 Mg Oral Capsule
Normalized name: dabigatran 150 mg oral capsule
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: frequency of heavy menstrual bleeding
Study: NCT04355689
Drug: NPI-001
Normalized name: NPI 32101
DrugBank: NPI 32101 (DB05264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT02922712
Drug: NISE
Normalized name: Anise
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nise 200mg Max per day in 2 divided doses
Study: NCT03583710
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03583710
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03583710
Drug: Mitotane
Normalized name: Mitotane
DrugBank: Mitotane (DB00648)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01430091
Drug: Prasugrel (clinical formulation)
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT01430091
Drug: Prasugrel (Orally Disintegrating Tablet [ODT])
Normalized name: prasugrel Oral Tablet
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT03791424
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administering premedication with sedative drug to relieve anxiety
Study: NCT04204902
Drug: Tepotinib 100 mg
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received a single oral dose of test treatment of tepotinib TF3 (5 \* 100 mg) in either treatment period 1 or 2.
Study: NCT04204902
Drug: Tepotinib 250 mg
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received a single oral dose of reference treatment of tepotinib TF3 (2 \* 250 mg) in either treatment period 1 or 2.
Study: NCT03656614
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)
Study: NCT03656614
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 40 µg/kg (Neostigmine 40) Neostigmine 55 µg/kg (Neostigmine 55) Neostigmine 70 µg/kg (Neostigmine 70)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow.
Study: NCT03165695
Drug: Ramelteon
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
Study: NCT03911271
Drug: 0.1% atropine and 0.01% atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
Study: NCT03911271
Drug: 0.01% atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.01% atropine for 24 months
Study: NCT03911271
Drug: 0.9% Sodium-chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo for 24 months
Study: NCT03389100
Drug: 18F-MK6240 injection
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
Study: NCT02777190
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
Study: NCT02124005
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01080547
Drug: mFolfox6 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional (mFolfox6) chemotherapy
Study: NCT02355509
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months
Study: NCT00069953
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During induction therapy, patients receive 15 mg/m\^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m\^2/day by IV over 1 hour beginning on days 57-61.
Study: NCT00069953
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During induction therapy, patients receive 200 mg/m\^2/day by IV over 2 hours on days 1 and 29.
Study: NCT04411069
Drug: Droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacients who had nausea and vomiting induced by chemotherapy will receive three anti emetic drugs: 4mg dexametasone, 4 mg ondansetron and 0,625 mg droperidol